As of January 15th, 2026
The pipeline page is updated quarterly. Please see the "Latest News" section for more information.
- Pre-Clinical
- P1
- P2
- P3
- Application
- Approval
Under Review: U.S., Vietnam, etc.
Partnered Party: HK inno.N Corporation
Licensed Territory: Worldwide
※区切り線が入ります。
- Pre-Clinical
- P1
- P2
- P3
- Application
- Approval
Phase 1 Completed: Japan
Partnered Party: HK inno.N Corporation
Licensed Territory: Worldwide
Read more
Close
Tegoprazan is a novel Potassium-Competitive Acid Blocker (P-CAB), a new type of gastric acid secretion inhibitor. Proton pump inhibitors (PPIs) have been used from long ago for gastroesophageal reflux disease, however, P-CAB as a new generation of drugs suppresses gastric acid secretion more rapidly and more persistently than PPIs.
枠を閉じる
- Pre-Clinical
- P1
- P2
- P3
- Application
- Approval
Pre-Clinical Studies Completed
Partnering Activity Underway
Licensed Territory: Worldwide
Read more
Close
RQ-00433412 is a novel ghrelin receptor agonist discovered by RaQualia. Ghrelin receptors regulate feeding and growth hormone secretion. Ghrelin receptor agonists are known to improve cachexia, weight loss, and anorexia in cancer patients. In addition to these effects, RQ-00433412 is expected to be an innovative new therapeutic option that improves quality of life of patients with constipation by promoting spontaneous bowel movement without causing diarrhea based on its gastrointestinal prokinetic effect.
枠を閉じる
- Pre-Clinical
- P1
- P2
- P3
- Application
- Approval
Phase 1 Ongoing: Australia
Partnered Party: Xgene Pharmaceutical Co. Ltd.
Licensed Territory: Worldwide excluding Japan
Read more
Close
RQ-00434739 is a novel Transient Receptor Potential Melastatin 8 (TRPM8) blocker discovered by RaQualia. TRPM8 is a temperature-sensitive ion channel that is activated by cold stimuli below 28 ℃ or menthol (a component of mint), and has been suggested to play roles in various pathological conditions including pain. RQ-00434739 has shown efficacy in animal models of pain through a new mechanism of action different from those of existing drugs, and is expected to be a breakthrough new drug for chronic pain for which treatment satisfaction is still low.
枠を閉じる
- POC
- Pilot Study
- Pivotal Study
- Application
- Approval
POC Study ongoing
Partnered Party:Vetbiolix SAS
Licensed Territory: Worldwide
Read more
Close
RQ-00000010 is a novel, highly potent and highly selective 5-HT_{4} agonist. The neurotransmitter serotonin (5-HT) promotes intestinal motility via 5-HT_{4}, one of the receptors in the digestive system, and its agonist is considered useful as a treatment for intestinal motility disorders. RaQualia has achieved good results in terms of both efficacy and safety in the development of this product so far, and expects that further development by the licensee will lead to a breakthrough new drug first for dogs and cats for which treatment options are limited.
枠を閉じる
All List of Programs
As of January 15th, 2026
|
Program |
Generic Name Compound Code |
Indication |
Licensed Territory |
Development Stage |
Partnered Party |
|
Potassium-Competitive Acid Blocker (P-CAB) |
tegoprazan RQ-00000004 |
Gastroesophageal Reflux Disease |
Worldwide |
Launched: Korea, China, the Philippines, Indonesia, Latin American countries including Mexico, etc., 19 countries in total Under NDA Review/NDA in Preparation: U.S., Vietnam, etc. Phase 1 Completed: Japan |
HK inno.N Corporation |
|
Ghrelin Receptor Agonist |
capromorelin RQ-00000005 |
Anorexia (dogs) |
Worldwide (Animals) |
Marketed: U.S. |
Elanco Animal Health Inc. |
|
Management of Weight Loss Associated with CKD (cats) |
Worldwide (Animals) |
Marketed: U.S., France, Belgium, Japan, Brazil |
|||
|
Approval: Other European nations including U.K., Canada etc. |
|||||
|
RQ-00433412 |
Constipation, Cancer-Related Anorexia/Cachexia Syndrome |
Worldwide |
Pre-Clinical Studies Completed |
- |
|
|
EP4 Antagonist |
grapiprant RQ-00000007 |
Osteoarthritis (dogs) |
Worldwide (Animals) |
Marketed: U.S., Europe, Japan etc. |
Elanco Animal Health Inc. |
|
Pain |
Worldwide (Human) |
Phase 2a Completed: U.S. |
AskAt Inc. |
||
|
Phase 1 Completed: China |
|||||
|
Cancer |
Worldwide (Human) |
Phase 1b Ongoing: U.S. |
|||
|
Phase 1 Ongoing: China |
|||||
|
RQ-00000008 |
Osteoarthritis Autoimmune Disorders |
Worldwide (Human) |
Pre-Clinical Studies Completed |
||
|
Osteoarthritis and Others |
Worldwide (Animals) |
Pre-Clinical Studies Ongoing |
|||
|
5-HT_{4} Partial Agonist |
RQ-00000009 |
Alzheimer's |
Worldwide |
Phase 1 Completed: U.S. |
|
|
COX-2 Inhibitor |
RQ-00317076 |
Pain |
Worldwide |
Phase 2a Completed: U.S. |
|
|
Worldwide |
Phase 1 Ongoing: China |
||||
|
Pain (Animals) |
Worldwide (Animals) |
Discovery Studies completed |
|||
|
CB2 Agonist |
RQ-00202730 |
Pain |
Worldwide |
Phase 1 Ongoing: UK |
|
|
Selective Sodium Channel Blocker |
Undisclosed |
Pain, Itch |
Worldwide |
- |
- |
|
P2X7 Receptor Antagonist |
RQ-00466479 AK1780 LY3857210 |
- |
Worldwide |
Undisclosed |
Asahi Kasei Pharma Corporation / Eli Lilly and Company |
|
TRPM8 Blocker |
RQ-00434739 XG2002 |
Chronic Pain |
Worldwide Excluding Japan |
Phase 1 Ongoing: Australia |
Xgene Pharmaceutical Co. Ltd. |
|
Pain |
Japan |
Preparation for Pre-Clinical Studies |
- |
||
|
Sodium Channel Blocker |
RQ-00350215 |
Pain |
Worldwide |
Undisclosed |
Hisamitsu Pharmaceutical Co., Inc. |
|
5-HT_{4} Agonist |
RQ-00000010 |
Gut Motility Disorders (dogs, cats) |
Worldwide (Animals) |
POC Study Ongoing |
Vetbiolix SAS |
|
Gastroparesis, Functional Dyspepsia, Chronic Constipation |
Worldwide (Human) |
Phase 1 Completed: UK |
- |
||
|
5-HT_{2B} Antagonist |
RQ-00310941 |
D-IBS, IBD-Remission Stage Symptoms |
Worldwide |
Phase 1 Completed: UK |
- |
|
Motilin Receptor Agonist |
RQ-00201894 |
Gastroparesis, Functional Dyspepsia, Post-Operative Ileus |
Worldwide |
Pre-Clinical Studies Completed |
- |
|
Certain four compounds |
Undisclosed |
Under evaluation |
Worldwide（Animals) |
Under evaluation |
Velovia Pharma, LLC |
|
Tamibarotene |
tamibarotene TM-411 |
Cancer |
Worldwide |
Clinical Stage |
- |
|
IRAK-M Degrader * |
FIM-001 |
Cancer |
Worldwide |
Pre-Clinical Studies Ongoing |
- |
* FIMECS, Inc. Development Program
Explore the list of our launched products.